Researching a peptide? Start with what the evidence actually shows.

Semaglutide — the compound behind Ozempic and Wegovy — is the most-studied peptide in the PSI library with over 4,500 indexed studies. It has FDA approval for weight management and type 2 diabetes, backed by large cardiovascular outcomes trials.

Retatrutide is a triple-agonist — it targets three receptors instead of the one or two that Ozempic and Mounjaro use. In the TRIUMPH-4 trial, it produced the largest weight loss ever recorded in a controlled drug trial. It is not yet FDA-approved.

BPC-157 is the compound that brings most people to peptide research. The animal data on tissue repair is among the strongest in the field. Human trials are underway but the dataset is still small.

Semax is prescribed in Russia for stroke and cognitive conditions, but it has no FDA approval in the United States. Researchers are studying its effects on BDNF — a protein critical for brain cell survival and new neural connections.

MOTS-c is a mitochondrial peptide that researchers call an "exercise mimetic" — it appears to activate some of the same metabolic pathways as physical exercise. Most research is preclinical, but the implications for aging and metabolic health have made it one of the most-watched compounds in the field.